At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,282 enrolled
Drug / intervention
KIF6 genetic testgenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Additional KIF6 Risk Offers Better Adherence to Statins
In Brief
An observational study evaluating KIF6 genetic test for Cardiovascular Diseases and Dyslipidemia. Completed, enrolled 1,282 participants across 1 site.
Detailed Summary
Many patients prescribed statins to lower their cholesterol stop taking their statin over time. The purpose of this study is to determine whether providing subjects their KIF6 carrier status (associated with increased cardiovascular event risk) will improve adherence to statin medications.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Diseases, Dyslipidemia
CountriesUnited States
CollaboratorsCelera Genomics
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2010
Enrollment StartMar 2010
Primary CompletionApr 2011
TodayJul 2026
First PostedFeb 15, 2010
Enrollment StartMar 1, 2010
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 16.4 years ago
Interventions
KIF6 genetic testgenetic
KIF6 carrier status with interpretation sheet provided to subject